Naringin for Health & Longevity - Quick Reference Sheet

Naringin for Health & Longevity

Created on 06/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Naringin is a citrus flavonoid the body converts into the more active naringenin. Laboratory and animal research shows wide-ranging promise — calming inflammation, reducing cell damage, improving blood fats, and protecting organs — but human evidence is scarce and absorption is poor, so its real value for long-term health remains genuinely uncertain. (Full Review)

Protocol

Common Supplemental Range
250–500 mg/day
Provisional; extrapolated from research and labels, not definitive human efficacy trials.
Dosing Schedule
Split, with meals
Short half-life and poor bioavailability favor twice-daily dosing; food aids tolerability.
Whole-Food & Extract Approach
Grapefruit or citrus-flavonoid extracts
Many practitioners favor the natural matrix (e.g., bergamot) over isolated naringin.
Time to effect
Lipid & Inflammatory Effects
Weeks to a few months
Consistent with how dietary flavonoids act; no rapid, perceptible acute effect.

Benefits

Contraindications
  • Immunosuppressant users (tacrolimus, cyclosporine)
  • Narrow-therapeutic-index CYP3A4 substrates
  • Pregnancy or breastfeeding
  • Significant liver impairment (Child-Pugh Class C)
Key Interactions
  • CYP3A4-metabolized prescription drugs (statins, calcium-channel blockers, immunosuppressants, some benzodiazepines)
  • OATP-transported drugs (some beta-blockers, fexofenadine)
  • Over-the-counter medications (some antihistamines)
  • Supplement interactions (bergamot extract, red yeast rice, plant sterols, other CYP3A4-inhibiting botanicals)
  • Additive lipid-lowering supplements (bergamot, berberine, soluble fiber, plant sterols)
  • Whole grapefruit consumption

Risk & Side Effects

  • High:
  • Medium:
  • Low: Drug-metabolism interaction potential; gastrointestinal upset
  • Speculative: Theoretical effects at supraphysiological doses; pregnancy and lactation uncertainty

Monitoring

Marker Target Why
LDL cholesterol < 100 mg/dL Tracks the most plausible lipid benefit
Triglycerides < 80 mg/dL Flavanones may modestly lower triglycerides
HDL cholesterol > 50 mg/dL (women), > 40 mg/dL (men) Possible small increase reported
hs-CRP < 1.0 mg/L Reflects the anti-inflammatory effect, if any
ALT / AST ALT < 25 U/L, AST < 25 U/L Safety: detects any liver stress at higher doses
eGFR / creatinine eGFR > 90 mL/min/1.73 m² Safety: monitors kidney function with chronic use
Fasting glucose 70–90 mg/dL Tracks any metabolic effect

Cadence: Baseline before starting; retest at 8–12 weeks, then every 6–12 months if continued, with liver and kidney function checked if used at concentrated doses long-term.

Qualitative Assessment

  • Digestive comfort (any nausea or stomach upset after dosing)
  • General energy levels
  • Any new effects from concurrent medications (a sign of a possible interaction)
  • Subjective sense of well-being over the monitoring window